References
- Aroldi F, Prochilo T, Bertocchi P, et al (2015). Oxaliplatininduced hypersensitivity reaction: underlying mechanisms and management. J Chemother, 27, 63-6. https://doi.org/10.1179/1973947814Y.0000000204
- Anderson BJ, Peterson LL (2015). Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer. J Oncol Pharm Pract, 12, 1078155215591388. https://doi.org/10.1177/1078155215591388
- Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, et al (2015). Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy, 70, 784-94. https://doi.org/10.1111/all.12620
- Arotcarena R, Berthelemy P, Piot M, et al (2001). Readministration of oxaliplatin using a rapid desensitization method after severe anaphylactic reaction. Gastroenterol Clin Biol, 25, 206-7.
- Alliot C, Messouak D, Beets C, et al (2001). Severe anaphylactic reaction to oxaliplatin. Clin Oncol (R Coll Radiol), 13, 236.
- Benedik J (2015). Hypersensitivity: case report. Reactions, 1534, 137.
- Bahl M, Dean T (2015). An intermediate step for the management of hypersensitivity to platinum and taxane chemotherapy. Curr Oncol, 22, 220.
- Brockow K, Przybilla B, Aberer W, et al (2015). Guideline for the diagnosis of drug hypersensitivity reactions. Allergo J Int, 24, 94-105.
- Bano N, Najam R, Qazi F, et al (2014). Gastrointestinal Adverse Effects in Advanced Colorectal Carcinoma Patients Treated with Different Schedules of FOLFOX. Asian Pac J Cancer Prev, 15, 8089-93. https://doi.org/10.7314/APJCP.2014.15.19.8089
- Boulanger J, Boursiquot JN, Cournoyer G, et al (2014). Comite de l’evolution des pratiques en oncologie. Curr Oncol, 21, 630-41. https://doi.org/10.3747/co.21.1966
- Baretta Z, Falci C, Piva E et al (2013). Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report. Clin Colorectal Cancer, 4, 294-96.
- Breslow RG, Caiado J, Castells MC (2009). Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol, 102, 155-60. https://doi.org/10.1016/S1081-1206(10)60247-5
- Caiado J, Castells M (2015). Presentation and diagnosis of hypersensitivity to platinum drugs. Curr Allergy Asthma Rep, 15, 1-9. https://doi.org/10.1007/s11882-014-0501-1
- Cheng LC, Chen HH, Lin SE, et al (2008). Hypersensitivity reactions to oxaliplatin: a prospectively collected study of 25 cases treated in one institute. J Soc Colon Rectal Surgeon (Taiwan), 19, 115-21. https://doi.org/10.1053/j.scrs.2008.02.008
- Cobo F, De Celis G, Pereira A, et al (2007). Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. Anti-Cancer Drugs, 18, 973-6.
- Curtis BR, Kaliszewski J, Marques MB, et al (2006). Immunemediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol, 81, 193-8.
- Dodgshun AJ, Hansford JR, Cole T, et al (2016). Carboplatin hypersensitivity reactions in pediatric low grade glioma are protocol specific and desensitization shows poor efficacy. Pediatr Blood Cancer, 63, 17-20. https://doi.org/10.1002/pbc.25686
- De Vries RS, Mattijssen EJ, van Sorge AA, (2006). Serious delayed hypersensitivity reaction to oxaliplatin. Ann oncol, 17, 1723-4. https://doi.org/10.1093/annonc/mdl116
- De Gramont A, Vignoud J, Tournigand C, et al (1997). Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hours continuous infusion in pre-treated metastatic colorectal cancer. Eur J Cancer, 33, 214-9. https://doi.org/10.1016/S0959-8049(96)00370-X
- Florit-Sureda M, Conde-Estevez D, Vidal J, et al (2015). Hypersensitivity reaction caused by folinic acid administration: a case report and literature review. J Chemother. [Epub ahead of print]
- Forcello NP, Khubchandani S, Patel SJ, et al (2015). Oxaliplatininduced immune-mediated cytopenias: A case report and literature review. J Oncol Pharm Pract, 21, 148-56. https://doi.org/10.1177/1078155213520262
- Giavina-Bianchi P, Aun MV, Galvao VR, et al (2015). Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs. Curr Treat Options Allergy, 2, 268-85. https://doi.org/10.1007/s40521-015-0060-2
- Gutierrez M, Pautier P, Lhomme C, et al (2002). Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin. J Clin Oncol, 20, 353. https://doi.org/10.1200/JCO.2002.20.1.353
- Gerard B, Bleiberg H, Van Daele D, et al (1998). Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs, 9, 301-05. https://doi.org/10.1097/00001813-199804000-00002
- Ichikawa Y, Goto A, Hirokawa S, et al (2009). Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol, 39, 616-20. https://doi.org/10.1093/jjco/hyp070
- Kim JY, Lim KH, Song WJ, et al (2015). Breakthrough Reactions during Oxaliplatin Desensitization: An Analysis of 177 Cases. J Allergy Clin Immunol, 135, 112.
- Kumaran D, Rupa D, Haresh KP, et al (2015). Oxaliplatin induced pulmonary toxicity-a rare phenomenon. Cancer Treat Commun, 4, 203-5. https://doi.org/10.1016/j.ctrc.2015.11.002
- Kurian S, Macintyre J, Mushtaq M, et al (2012). Oxaliplatin induced disseminated intravascular coagulation: A case report and review of literature. World J Gastrointest Oncol, 4, 181. https://doi.org/10.4251/wjgo.v4.i7.181
- Lee SY, Kim MY, Kim MH, et al (2013). Hypersensitivity reactions to oxaliplatin: outcomes of premedication and desensitization. J Allergy Clin Immunol, 131, 166.
- Lundqvist EÅ, Fujiwara K, Seoud M (2015). Principles of chemotherapy. Int J Gynaecol Obstet, 131, 146-9. https://doi.org/10.1016/j.ijgo.2015.06.011
- Leguy-Seguin V, Jolimoy G, Coudert B, et al (2007). Diagnostic and predictive value of skin testing in platinum salt hypersensitivity, J Allergy Clin Immunol, 119, 726-30. https://doi.org/10.1016/j.jaci.2006.11.640
- Lenz HJ (2007). Management and preparedness for infusion and hypersensitivity reactions. Oncologist, 12, 601-9. https://doi.org/10.1634/theoncologist.12-5-601
- Larzilliere I, Brandissou S, Breton P, et al (1999). Anaphylactic reaction to oxaliplatin: a case report. Am J Gastroenterol, 94, 3387-8. https://doi.org/10.1016/S0002-9270(99)00635-8
- Malkhasyan K, Halene S, Lacy J, et al (2015). Oxaliplatin- Related Acute Disseminated Intravascular Coagulation Syndrome in a Patient With Metastatic Colon Cancer. Clin Colorectal Cancer, 14, 9-12. https://doi.org/10.1016/j.clcc.2014.09.011
- Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, et al (2013). Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy, 68, 853-61. https://doi.org/10.1111/all.12105
- Meyer L, Zuberbier T, Worm M, et al (2002). Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule [letter]. J Clin Oncol, 20, 1146-7. https://doi.org/10.1200/JCO.2002.20.4.1146
- Markman M, Kennedy A, Webster K, et al (1999). Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol, 17, 1141-5. https://doi.org/10.1200/JCO.1999.17.4.1141
- Maindrault-Goebel F, Louvet C, Andre T, et al (1999). Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer, 35, 1338-42. https://doi.org/10.1016/S0959-8049(99)00149-5
- Machover D, Diaz-Rubio E, de Gramont A, et al (1999). Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol, 7, 95-8.
- Nisi C, Moretti A, Donati D, et al (2015). E18A post-reaction regimen for CRC patients manifesting hypersensitivity to oxaliplatin: an effective alternative not to rule out an important option of treatment. Ann Oncol, 26, 41.
- Okayama T, Ishikawa T, Sugatani K, et al (2015). Hypersensitivity reactions to oxaliplatin: identifying the risk factors and judging the efficacy of a desensitization protocol. Clin Ther, 37, 1259-69. https://doi.org/10.1016/j.clinthera.2015.03.012
- Osumi H, Shinozaki E, Kumekawa Y, et al (2013). Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy. Gan Kagaku Ryoho, 40, 1557-60.
- Pedersen KS (2015). Safety and efficacy of desensitization protocols for platinum hypersensitivity reactions. Pancreas, 2, 10.
- Pagani M (2015). Hypersensitivity, urticaria and dyspnoea: 6 case reports. Reactions, 1567, 168-5.
- Parel M, Ranchon F, Nosbaum A, (2014). Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol, 15, 1. https://doi.org/10.1186/2050-6511-15-1
- Polyzos A, Tsavaris N, Kosmas C, et al (2001). Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncol, 61, 129-33. https://doi.org/10.1159/000055363
- Syrigou EI (2015). Hypersensitivity reaction: case report. Reactions, 1533, 343-10.
- Santini D, Tonini G, Salerno A, et al (2001). Idiosyncratic reaction after oxaliplatin infusion [letter]. Ann Oncol, 12, 132-3. https://doi.org/10.1023/A:1008366223918
- Schüll B, Kornek GV, Scheithauer W (2001). Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule. Ann Oncol. 12, 1653-4.
- Shukunami K, Kurokawa T, Kubo M, et al (1999). Hypersensitivity reaction to carboplatin during treatment for ovarian cancer: successful resolution by replacement with cisplatin. Tumori, 85, 297-8. https://doi.org/10.1177/030089169908500418
- Shlebak AA, Clark PI, Green JA (1995).Hypersensitivity and cross reactivity to cisplatin and analogues. Cancer Chemother Pharmacol, 35, 349-51. https://doi.org/10.1007/BF00689458
- Spearing RL, Hickton CM, Sizeland P, et al (1990). Quinineinduced disseminated intravascular coagulation. Lancet, 336, 1535-7. https://doi.org/10.1016/0140-6736(90)93309-D
- Tham EH, Cheng YK, Tay MH, et al (2015). Evaluation and management of hypersensitivity reactions to chemotherapy agents. Postgrad Med J, 91, 145-50. https://doi.org/10.1136/postgradmedj-2014-132686
- Tamura H (2015). Anaphylactic shock leading to cardiopulmonary arrest: case report. Reactions, 1552, 171-23.
- Toki MI, Saif MW, Syrigos KN (2014). Hypersensitivity reactions associated with oxaliplatin and their clinical management. Expert Opin Drug Saf, 13, 1545-54. https://doi.org/10.1517/14740338.2014.963551
- Taleghani BM, Meyer O, Fontana S, et al (2005). Oxaliplatininduced immune pancytopenia. Transfusion, 45, 704-8. https://doi.org/10.1111/j.1537-2995.2005.04373.x
- Thomas RR, Quinn MG, Schuler B, et al (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 97, 2301-7. https://doi.org/10.1002/cncr.11379
- Tonini G, Santini D, Vincenzi B, et al (2002). Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents, 16, 105-9.
- Tournigand C, Maindrault-Goebel F, Louvet C, et al (1998). Severe anaphylactic reactions to oxaliplatin. Eur J Cancer, 34, 1297-8. https://doi.org/10.1016/S0959-8049(98)00064-1
- Wang AL, Patil SU, Long AA, et al (2015). Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. Ann Allergy Asthma Immunol, 115, 422-8. https://doi.org/10.1016/j.anai.2015.07.017
- Wang JH, King TM, Chang MC, et al (2012). Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol, 18, 5427-33. https://doi.org/10.3748/wjg.v18.i38.5427
- Yamauchi H, Goto T, Takayoshi K, et al (2015). A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin. Eur J Cancer Care, 24, 111-6. https://doi.org/10.1111/ecc.12156
- Yanagihara Y (2015). Allergic reaction and fever: 2 case reports. Reactions, 1555, 147-3.
- Yoshida Y, Hirata K, Matsuoka H, et al (2015). A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the aVOiD trial. Drug Des Devel Ther, 9, 6067-73.
- Zanotti KM, Rybicki LA, Kennedy AW, et al (2001). Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol, 19, 3126-9. https://doi.org/10.1200/JCO.2001.19.12.3126
Cited by
- Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer vol.79, pp.5, 2017, https://doi.org/10.1007/s00280-017-3294-9
- Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer vol.35, pp.11, 2018, https://doi.org/10.1177/1049909118773995